Equities

Wellell Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4106:TAI

Wellell Inc

Actions
Health CareMedical Equipment and Services
  • Price (TWD)23.10
  • Today's Change0.00 / 0.00%
  • Shares traded63.91k
  • 1 Year change-5.71%
  • Beta0.1655
Data delayed at least 20 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Wellell Inc, formerly Apex Medical Corp, is a Taiwan-based company principally engaged in the manufacture, trading, import and export of medical and healthcare related equipment. The main products include the wound management (WM) series, respiratory therapy (RT) series, welfare equipment, as well as the electronic medical devices (EMD) series, such as four-wheel walk helpers, crutches, wheelchairs, shower devices, automatic positive airway pressure (APAP) devices, interferential stimulators, electrical muscle stimulators (EMSs) and liquid crystal display (LCD) massage devices. The Company mainly distributes products to Europe, the Americas and Asia.

  • Revenue in TWD (TTM)2.39bn
  • Net income in TWD138.72m
  • Incorporated1990
  • Employees535.00
  • Location
    Wellell IncNo.9Min Sheng Street, Peibei LiTucheng DistrictNEW TAIPEI 236TaiwanTWN
  • Phone+886 222685568
  • Fax+886 222689521
  • Websitehttps://www.wellell.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
OK Biotech Co Ltd1.64bn68.75m2.05bn62.0030.510.809411.981.250.46390.463911.3217.480.44782.622.98--2.292.732.903.6027.0118.755.115.561.173.920.3009111.0540.116.113,087.75-5.6637.07-24.66
Wellell Inc2.39bn138.72m2.32bn535.0016.900.95459.620.97091.371.3723.6024.200.75332.786.25--4.404.075.475.3546.1542.355.855.301.99--0.118456.36-9.843.23-24.275.5613.4212.20
A Plus Biotechnology Co Ltd825.52m171.54m2.87bn--15.362.2914.483.485.405.4025.9336.220.62530.81836,551.74--13.005.5214.856.5569.5365.4920.799.744.42--0.073575.9414.0110.18384.7937.118.86--
Data as of Feb 11 2026. Currency figures normalised to Wellell Inc's reporting currency: Taiwan Dollar TWD

Institutional shareholders

0.51%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 05 Feb 2026461.46k0.46%
Dimensional Fund Advisors Ltd.as of 30 Nov 202549.03k0.05%
DFA Australia Ltd.as of 30 Nov 20252.13k0.00%
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.